The future of technologies for personalised medicine

New Biotechnology

Volumn 29, Issue 6, 2012, Pages 625-633

  Harvey, Alison ^a   Brand, Angela ^b,d   Holgate, Stephen T ^b,e   Kristiansen, Lars V ^c   Lehrach, Hans ^b,f   Palotie, Aarno ^b,g,h   Prainsack, Barbara ^b,i  

^a Finchley Court ^*  (United Kingdom)

^b Scientific Committee for the ESF Forward Look on Personalised Medicine for the European Citizen   (France)

^c European Science Foundation   (France)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^g UNIVERSITY OF HELSINKI   (Finland)

^h WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

ⁱ BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DATA COLLECTION; EFFECTIVE TRANSLATION; MOLECULAR LEVELS; PERSONALISED MEDICINES; REGULATORY FRAMEWORKS; RESEARCH ACTIVITIES; SCIENTIFIC RESEARCHES; SYSTEM-LEVEL FUNCTIONING;

HEALTH CARE; RESEARCH;

INTEGRATION;

AGE; ARTICLE; COMPUTER MODEL; DATA PROCESSING; DECISION SUPPORT SYSTEM; EVIDENCE BASED MEDICINE; FAMILY HISTORY; GENDER; INTEGRATION; MEDICAL PRACTICE; MEDICAL RESEARCH; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESOURCE MANAGEMENT; TRANSLATIONAL RESEARCH;

HEALTH INFORMATION SYSTEMS; HEALTH RESOURCES; HUMANS; INDIVIDUALIZED MEDICINE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84865415689     PISSN: 18716784     EISSN: 18764347     Source Type: Journal    
DOI: 10.1016/j.nbt.2012.03.009     Document Type: Article

References (57)

1. Hood L., et al. Systems biology and new technologies enable predictive and preventative medicine. Science 2004, 306:640-643.
2. Abrahams E. Right drug, right patient, right time: personalized medicine coalition. Clin. Transl. Sci. 2008, 1:11-12.
3. Galas D., Hood L. Systems biology and emerging technologies will catalyze the transition from reactive medicine to predictive, personalized, preventive and participatory (P4) medicine. Interdiscip. Biol. Central 2009, 1:0006.
4. Ginsburg G.S., Willard H.F. Genomic and personalized medicine: foundations and applications. Transl. Res. 2009, 154:277-287.
5. Green E.D., Guyer M.S. Charting a course for genomic medicine from base pairs to bedside. Nature 2011, 470:204-213.
6. Berg M. Turning a practice into a science: reconceptualizing post-war medical practice. Soc. Stud. Sci. 1995, 25:437-476.
7. Sackett D., et al. Evidence-based medicine: what it is and what it isn't. Br. Med. J. 1996, 312:71-72.
8. Timmermans S., Berg M. The Gold Standard: The Challenge of Evidence-based Medicine and Standardization in Health Care 2003, Temple University Press, Philadelphia.
9. Ferraldeschi R., Newman W.G. Pharmacogenetics and pharmacogenomics: a clinical reality. Ann. Clin. Biochem. 2011, 48:410-417.
10. Hedgecoe A. The Politics of Personalised Medicine: Pharmacogenetics in the Clinic 2004, Cambridge University Press, Cambridge.
11. Brand A. Public health genomics - public health goes personalized?. Eur. J. Public Health 2011, 21:2-3.
12. Editorial Complicated is not complex. Nat. Biotechnol. 1999, 17:511.
13. Khoury M.J., et al. The scientific foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet. Med. 2009, 11:559-567.
14. Green R.C., et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N. Engl. J. Med. 2009, 361:245-254.
15. Miles A., et al. Evidence-based healthcare, clinical knowledge and the rise of personalised medicine. J. Eval. Clin. Pract. 2008, 14:621-649.
16. Rabeharisoa V., Callon M. The involvement of patients' associations in research. Int. Soc. Sci. J. 2002, 171:57-65.
17. Novas C. The political economy of hope: patients' organizations, science and biovalue. BioSocieties 2006, 1:289-305.
18. Panofsky A. Generating sociability to drive science: patient advocacy organizations and genetics research. Soc. Stud. Sci. 2011, 41:31-57.
19. Anon. Garage biology. Nature 2010, 467:634.
20. Wicks P., et al. Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm. Nat. Biotechnol. 2011, 29:411-414.
21. Fornai F., et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2052-2057.
22. Wanless D. Securing Good Health for the Whole Population 2004, HM Treasury, London.
23. Brand A., Brand H. Health literacy and public health genomics: innovation management by citizens: editorial. Public Health Genomics J. 2011, 14:193-194.
24. Huang S. The practical problems of post-genomic biology. Nat. Biotechnol. 2000, 18:471-472.
25. Kitano H. Looking beyond the details: a rise in system-oriented approaches in genetics and molecular biology. Curr. Genet. 2002, 41:1-10.
26. Khatib F., et al. Crystal structure of a monomeric retroviral protease solved by protein folding game players. Nat. Struct. Mol. Biol. 2011, 18:1175-1177.
27. Prainsack B., et al. Misdirected precaution. Nature 2008, 456:34-35.
28. Prainsack B. Voting with their mice: personal genome testing and the participatory turn in disease research. Account. Res. 2011, 18:132-147.
29. Marincola F. Translational medicine: a two-way road. J. Transl. Med. 2003, 1.
30. Wainwright S.P., et al. From bench to bedside? Biomedical scientists' expectations of stem cell science as a future therapy for diabetes. Soc. Sci. Med. 2006, 63:2052-2064.
31. Carrel T. The relationship between surgeon and basic scientist. Transpl. Immunol. 2002, 9:331-337.
32. Sartor R.B. Translational research: bridging the widening gap between basic and clinical research. Gastroenterology 2003, 124:1178.
33. Archer S.L. The making of a physician-scientist-the process has a pattern: lessons from the lives of Nobel laureates in medicine and physiology. Eur. Heart J. 2007, 28:510-514.
34. Calvert J. Systems biology, interdisciplinarity and disciplinary identity. Collaboration in the New Life Sciences 2010, Ashgate, Aldershot. J.N. Parker, N. Vermeulen, B. Penders (Eds.).
35. Lewis J. Matchmaking mechanisms: collaborative arrangements in proteomics and bioinformatics. Collaboration in the New Life Sciences 2010, Ashgate, Aldershot. J.N. Parker, N. Vermeulen, B. Penders (Eds.).
36. Hogarth, S. (2011) Regulatory experiments and transnational networks: the governance of pharmacogenomics in Europe and the United States. Global Biopolitics Research Group: Working paper 36. (; accessed 20.10.11). http://www.kcl.ac.uk/sspp/departments/politicaleconomy/research/biopolitics/publications/workingpapers/workingpapers31-37.aspx.
37. Morre S.A., et al. The EU FP6 EpiGenChlamydia Consortium: contribution of molecular epidemiology and host-pathogen genomics to understanding Chlamydia trachomatis-related disease. Drugs Today 2009, 45:7-13.
38. Rosenkötter N., et al. The contribution of health technology assessment, health needs assessment, and health impact assessment to the assessment and translation of technologies in the field of public health genomics. Public Health Genomics 2010, 14:43-52.
39. Tung J.Y., et al. Efficient replication of over 180 genetic associations with self-reported medical data. PLoS One 2011, 6:e23473.
40. Taylor P. When consent gets in the way. Nature 2008, 456:32-33.
41. Prainsack B., Buyx A. Solidarity: Reflections on an Emerging Concept in Bioethics 2011, Nuffield Council on Bioethics, London.
42. Office of Public Services Reform Putting People at the Heart of Public Services 2005, Office of Public Services Reform, London.
43. Pardridge W. Translational science: what is it and why is it so important?. Drug Discov. Today 2003, 8:813-815.
44. Osborne T. Against 'creativity': a philistine rant. Econ. Soc. 2003, 32:507-525.
45. Deleuze G. Mediators. Incorporations 1992, New York, Zone Books. J. Crary, S. Kwinter (Eds.).
46. Rose N. The Politics of Life Itself 2006, Princeton University Press, Princeton, NJ.
47. Bauman Z. Survival as a social construct. Theory Cult. Soc. 1992, 9:1-36.
48. Illich I. Limits to Medicine (Medical Nemesis: The Expropriation of Health) 1977, Penguin, Harmondsworth.
49. Sander C. Genomic medicine and the future of health care. Science 2000, 287:1977-1978.
50. Whitney A.R., et al. Individuality and variation in gene expression patterns in human blood. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:1896-1901.
51. Eady J.J., et al. Variation in gene expression profiles of peripheral blood mononuclear cells from healthy volunteers. Physiol. Genomics 2005, 22:402-411.
52. Dumeaux V., et al. Deciphering normal blood gene expression variation-The NOWAC postgenome study. PLoS Genet. 2010, 6:e1000873.
53. Carlson J.M., Doyle J. Complexity and robustness. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(Suppl. 1):2538-2545.
54. Kitano H. Biological robustness. Nat. Rev. Genet. 2004, 5:826-837.
55. Stelling J., et al. Robustness of cellular functions. Cell 2004, 118:675-685.
56. Elliott R., et al. Nutrigenomic approaches for benefit-risk analysis of foods and food components: defining markers of health. Br. J. Nutr. 2007, 98:1095-1100.
57. Kitano H. Towards a theory of biological robustness. Mol. Syst. Biol. 2007, 3:137.